This clinical trial is focused on studying the long-term safety and tolerability of a treatment called itepekimab in individuals with Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic lung disease that makes it difficult to breathe and can lead to coughing, wheezing, and shortness of breath. The treatment being tested, itepekimab, is a solution for injection that is administered using a pre-filled syringe. It is a type of medication known as a monoclonal antibody, which is designed to target specific proteins in the body that may contribute to inflammation and other symptoms associated with COPD.

The purpose of this study is to evaluate how safe and well-tolerated itepekimab is over a longer period in people who have already participated in previous studies involving this treatment. Participants in this study will have previously completed a treatment period in one of two earlier clinical studies. During the study, participants will receive either itepekimab or a matched placebo, which is a substance that looks like the treatment but does not contain the active ingredient. The study will monitor participants for any side effects or reactions to the treatment, as well as measure the levels of itepekimab in the blood.

Throughout the study, researchers will also observe how often participants experience flare-ups of their COPD symptoms, known as acute exacerbations, and how long it takes for these flare-ups to occur. Additionally, changes in lung function and quality of life from the baseline of the previous studies will be assessed. The study aims to provide valuable information on the long-term use of itepekimab in managing COPD symptoms and improving patient outcomes.